Source: International Congress 2016 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ebymar Arismendi Nunez (Barcelona, Spain), María del Carmen Vennera, Mariona Pascal, Ebymar Arismendi Nunez, César Picado. Total and free IgE in evolution of severe asthma after omalizumab treatment. Eur Respir J 2016; 48: Suppl. 60, 4117

Member's Comments

No comment yet.

Related content which might interest you: Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Asthma control, symptoms and exacerbations across treatment levels in patients with asthma Source: Annual Congress 2013 –Management of respiratory diseases in primary care Year: 2013 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Long-term efficacy of omalizumab (OMA) for patients with severe allergic asthma (SAA). Clinical assessment and relationship to serum IgE concentrations Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015 Clinical effectiveness of anti-IgE therapy in severe asthma with fungus sensitization Source: International Congress 2014 – Non inflammatory monitoring of airway diseases Year: 2014 FeNO in children with asthma is related to inhaled corticosteroids adherence, not to asthma control Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 A clinically observed variability in serum total IgE in patients being considered for omalizumab therapy Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016